Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

Completed

Conditions studied: HIV Infections

In brief

HIV infected patients, aged \</= 35 years and aged \>/= 55 years, who are regularly taking either efavirenz (EFV) or lopinavir/ritonavir (Lop/r) as part of their antiretroviral regimen are being asked to spend 12 hours at the researchers' clinic (the ACS clinic at Jacobi Medical Center, Bronx, New York) for an intensive pharmacokinetic study in which 5 cc of blood will be drawn 9 times over a 12 hour period. Patients taking EFV will return for one additional blood draw the following day.

Key facts

Study ID

NCT00179335

Run by

Albert Einstein College of Medicine

People needed

45

Starts

2003-08-01

Expected to finish

2006-09-01

Last updated by the study team

2021-04-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV+
• Taking lopinavir/ritonavir or efavirenz
• Age </= 35 years or >/= 55 years

You may not qualify if…

• Concurrent therapy with drugs that alter lopinavir/ritonavir levels.
• Other renal or kidney disease.
• Chronic hepatitis B or C

Where it is running

• Jacobi Medical Center ACS Clinic — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.